70 year old man with Ca.prostate with osteoblastic secondaries in pelvis and lumbar vertebra showed well differentiated Adeno Carcinoma prostate on needle biopsy. He is idealy treated by –
**Core Concept**
The management of prostate cancer with osteoblastic metastases involves a multidisciplinary approach, considering the patient's overall health, disease extent, and potential treatment options. In this scenario, the patient's well-differentiated adenocarcinoma of the prostate with osteoblastic metastases to the pelvis and lumbar vertebrae requires a treatment plan that balances cancer control with quality of life.
**Why the Correct Answer is Right**
The ideal treatment for a patient with advanced prostate cancer and osteoblastic metastases is hormone therapy, specifically androgen deprivation therapy (ADT). This approach aims to decrease testosterone levels, which can slow the growth of prostate cancer cells. ADT can be achieved through various methods, including medical therapy (e.g., luteinizing hormone-releasing hormone (LHRH) agonists or antagonists) or surgical castration. In this case, the patient's well-differentiated adenocarcinoma suggests a slower-growing tumor, making ADT a suitable option to control the disease. The osteoblastic nature of the metastases also supports the use of ADT, as it can help reduce bone turnover and associated symptoms.
**Why Each Wrong Option is Incorrect**
* **Option A:** Radiation therapy may be considered for localized prostate cancer or bone metastases but is not the ideal choice for a patient with well-differentiated adenocarcinoma and osteoblastic metastases.
* **Option B:** Chemotherapy is typically reserved for castration-resistant prostate cancer or in combination with hormone therapy. It is not the first-line treatment for a patient with well-differentiated adenocarcinoma and osteoblastic metastases.
* **Option D:** Surgery, such as radical prostatectomy, is generally not recommended for patients with advanced prostate cancer and metastatic disease.
**Clinical Pearl / High-Yield Fact**
In patients with prostate cancer and osteoblastic metastases, hormone therapy is often the primary treatment approach. It is essential to monitor bone density and assess the patient's response to ADT, as it can help prevent bone-related complications and improve overall quality of life.
**Correct Answer: C.**